Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to ...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel ...

Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...

Specific ancient viral DNA sequences in the human genome are linked to genetic risk for multiple sclerosis and amyotrophic ...